Amonafide in patients with leiomyosarcoma of the uterus - A phase II Gynecologic Oncology Group study

Twenty-six evaluatable patients who had leiomyosarcoma of the uterus were treated with amonafide, 300 mg/m(2), for 5 consecutive days every 3 weeks. One partial response (4%) resulted. Hematologic toxicity was substantial, with grade 3 or 4 events occurring as follows: leukopenia, 12 patients (46%); thrombocytopenia, 4 patients (15%); and granulocytopenia, 7 patients (27%). One patient had transient grade 4 renal failure. Considering the poor activity and substantial toxicity that was observed, no further studies are planned by the Gynecologic Oncology Group using amonafide at this dose schedule in leiomyosarcomas.